$TRDA News

Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer

What's Going On With Entrada Therapeutics Stock Wednesday?

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Entrada Therapeutics Announces Independent Data Monitoring Committee Review Of All Available Safety And PK Data From The Eight Participants Enrolled In Cohort 2 Of The Double-Blind, Placebo-Controlled, Multiple Ascending Dose Portion of ELEVATE-44-201

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K Estimate

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical Trial

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

Entrada’s stock drops as DMD drug’s efficacy falls short

HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure